PT 150
Alternative Names: ORG-34517; PT150; SCH-900636Latest Information Update: 29 Sep 2025
At a glance
- Originator Organon
 - Developer Merck & Co; Organon; Pop Test
 - Class Antidepressants; Antineoplastics; Benzodioxoles; Chemosensitisers; Phenanthrenes; Steroids
 - Mechanism of Action Androgen receptor antagonists; Glucocorticoid receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- No development reported Alcoholism; Breast cancer; Cancer
 - Discontinued Major depressive disorder
 
Most Recent Events
- 22 Sep 2025 San Diego Veterans Healthcare System plans phase II trial in Post traumatic stress disorders in US in April 2026 (Parenteral) (NCT07187011)
 - 11 Dec 2024 Pop Test Oncology plans a phase I trial for Alcoholism in USA (PO) in January 2025 (NCT06712602)
 - 28 Jun 2024 No recent reports of development identified for preclinical development in Cancer in USA